

Vaccine Research and Development

Judith Perez*

Department of Immunology, Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA.

EDITORIAL

Vaccine is an organic solution which provides immunity against certain infectious diseases. It consists of a biological agent to simulate a disease causing microorganism and a weaker form of microbes, toxins or its surface proteins. These agents recognize any foreign particle entering into the body and indicate it as a threat in order to destroy it. Vaccine improves the active immunity against harmful agents. Vaccines also provide antibodies already released in another host. The administration includes parenteral administration, oral and sometimes nasal form.

Vaccine research is made possible with the help of biotechnology department. Due to the innovative studies regarding vaccines, vaccine development has been made possible for many infectious and dreadful diseases. The development of vaccine takes several steps.

The primary step in vaccine development is to include antigens in the drug. The level of antibody releasing activity has to be identified against the antigen in order to release the vaccine. A frequent research has been conducted. The second step includes preclinical studies. Tests are conducted by researchers to detect the ability of patient's immunogenicity. The formulation, toxicity development and manufacturing process has been done.

Then the next step will be clinical trials which have been conducted in three phases. The first phase includes the administration of vaccine to volunteered candidates in order to check the safety of drug. The second phase includes the monitoring of candidates for immunogenicity, doses, delivery methods and safety. The third phase generally involves a large number of candidates to test the side effects, efficacy and antibody production.

On behalf of the board of "The Journal of Vaccines and Vaccination" I am gratified to present the Volume 11 Issue 6 of the journal. The journal has been established in the year 2009 and has published 11 volumes. Our journal is running successfully since 10 years with utmost support and encouragement provided

by the editorial board members, readers, researchers and reviewers. Our articles include review, research, short communication, mini review, case reports etc.

Our journal has a lot of achievements in these successful years and resulted in the finest growth of the journal. The journal is an open access and a peer reviewed journal. It follows a double blinded peer review process in which the identity of authors and reviewers is not revealed to each other. It has indexing in PubMed, Schimago, Scholar and many other databases [1-5].

The journal includes topics related to vaccines such as cancer vaccines, veterinary vaccines, human vaccines, vaccine trials, HIV vaccines, malaria vaccines, TB vaccines, vaccine studies, vaccine regulatory issues, vaccine adjuvants, vaccine studies etc. The journal homepage provides every detail about the submission process of articles, publication fee, journal information, instructions for the authors and the citation reports etc. Researchers can easily find the journal information and submit their valuable manuscripts to the journal.

REFERENCES

1. Choudhury SA, Matin F. Seroprevalence of Antibodies to Tetanus Toxoid and Diphtheria Toxoid in Perinatally Human Immunodeficiency Virus (HIV) - Infected Children and Adolescents. *J Vaccines Vaccin.* (2020); 11(3): 1-4.
2. Thabelo M, Azubuike BN The Burden of Disease from Congenital Rubella Syndrome in Lesotho, south africa. *J Vaccines Vaccin.* (2020); 11(3): 1-7.
3. Misra S. Integrat ive Approach Amid COVID-19 Crisis -A Perspective, Rajkot, India *J Vaccines Vaccin.* (2020); 11(3):1-7.
4. Anirban D, Sonali S, Ahmed TMHM Understanding the Lacunae in Knowledge and Attitude Leading to Vaccine Hesitancy, India. *J Vaccines Vaccin.* (2020); 11(2):1-3.
5. Tazehkand MN, Hajipour O. Evaluating the Vaccine Potential of a Tetravalent Fusion Protein against Coronavirus. *J Vaccines Vaccin.* (2020) 11(2): 1-6.

Correspondence to: Judith Perez, Department of Immunology, Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA, E-mail: perezjudi@pfizer.com

Received: October 15, 2020; **Accepted:** October 30, 2020; **Published:** November 5, 2020

Citation: Perez J (2020) Vaccine Research and Development. *J Vaccines Vaccin* S5.e001.

Copyright: © 2020 Perez J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.